Soleno Therapeutics Inc Total Liabilities
Soleno Therapeutics Inc total liabilities. Based on the latest financial reports, Soleno Therapeutics Inc (SLNO) has total liabilities worth $112.59 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Soleno Therapeutics Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Soleno Therapeutics Inc (2012–2025)
Total liabilities of Soleno Therapeutics Inc from 2012 to 2025. This chart illustrates how Soleno Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Soleno Therapeutics Inc to see how much of total assets are deployed in long-term investments.
Soleno Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Soleno Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Betta Pharmaceuticals Co Ltd
SHE:300558
|
China | CN¥3.83 Billion |
|
Union Bank of Taiwan
TW:2838
|
Taiwan | NT$970.36 Billion |
|
Pinnacle Investment Management Group Ltd
AU:PNI
|
Australia | AU$331.46 Million |
|
Yongan Futures Co.Ltd.
SHG:600927
|
China | CN¥57.57 Billion |
|
AUB Group Ltd
AU:AUB
|
Australia | AU$2.77 Billion |
|
Fortuna Silver Mines Inc
TO:FVI
|
Canada | CA$569.64 Million |
|
NetScout Systems Inc
NASDAQ:NTCT
|
USA | $647.81 Million |
|
Steadfast Group Limited
F:1S6
|
Germany | €3.80 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Soleno Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Soleno Therapeutics Inc.
Liquidity & Leverage Metrics
Soleno Therapeutics Inc Total Liabilities Ratios Explained
Soleno Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Soleno Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Soleno Therapeutics Inc (2012–2025)
The table below shows the annual total liabilities of Soleno Therapeutics Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $113.72 Million | +32.44% |
| 2024-12-31 | $85.86 Million | +270.34% |
| 2023-12-31 | $23.18 Million | +43.56% |
| 2022-12-31 | $16.15 Million | -9.07% |
| 2021-12-31 | $17.76 Million | -8.62% |
| 2020-12-31 | $19.43 Million | -16.32% |
| 2019-12-31 | $23.23 Million | +82.33% |
| 2018-12-31 | $12.74 Million | +2.01% |
| 2017-12-31 | $12.49 Million | +486.33% |
| 2016-12-31 | $2.13 Million | -57.21% |
| 2015-12-31 | $4.98 Million | -73.42% |
| 2014-12-31 | $18.73 Million | -52.53% |
| 2013-12-31 | $39.45 Million | +7.47% |
| 2012-12-31 | $36.71 Million | -- |
About Soleno Therapeutics Inc
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeut… Read more